Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

Summary

This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.

Timeline

Start

2012-04

Primary completion

2015-04

Completion

—

Outcome

Outcome not reported

Stopped: “Study is no longer needed as recent data have answered the primary hypotheses for this study.”

Drugs

Indications